Here is the design of a clinical trial:

Official Title: The PREDMETH Trial: Effectiveness of Methotrexate Versus Prednisone As First-line Therapy for Pulmonary Sarcoidosis - a Randomized Controlled Trial

Included conditions:
- Sarcoidosis, Pulmonary

Study Armgroups:
- {'label': 'methotrexate', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Methotrexate']}
- {'label': 'prednisone', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Drug: Prednisone']}

Interventions:
- {'type': 'DRUG', 'name': 'Methotrexate', 'description': 'Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.', 'armGroupLabels': ['methotrexate']}
- {'type': 'DRUG', 'name': 'Prednisone', 'description': 'Oral prednisone (start 40 mg daily, to be tapered to 10 mg daily) for 24 weeks.', 'armGroupLabels': ['prednisone']}

Primary Outcomes:
- {'measure': 'Forced Vital Capacity (FVC)', 'description': 'Change in hospital-measured FVC between baseline and 24 weeks', 'timeFrame': '24 weeks after inclusion'}

Please estimate the sample size based on the assumption: 
One-sided test with a power of 80% (β) and a type 1 error of 5% (α). Allowance for 20% drop-out.
Sample size calculation
        The power calculation is based on data from a previous observational study with prednisone in newly treated patients with pulmonary sarcoidosis. In this study, the mean increase in FVC with prednisone was 15%, with a standard deviation of 10.5% [8]. In a case series of 50 patients with sarcoidosis treated with methotrexate, treatment effect was in line with the findings for prednisone; 66% of patients had more than 15% improvement in vital capacity after 6âmonths [24]. We chose a non-inferiority margin of 5%, because FVC measurements show biological variation and thus variation <â5% is not considered clinically relevant. Based on these numbers, using a one-sided test with a power of 80% (Î²) and a type 1 error of 5% (Î±), the estimated sample size of this study is 110 patients. To allow for 20% drop-out, we aim to randomize 138 patients.